Previous Webinar

Anke Mueller-Fahrnow was head of Lead Discovery Berlin within Bayer AG, where she was responsible for Protein Technologies, Structural Biology and for High Throughput Screening. She is now Vice President, Senior Scientific Advisor at Innovation Campus Berlin, Nuvisan. Her research activities are mainly focused on oncology and gynecological therapies. Since July, Anke is the chair of SGC board of directors.

Aled Edwards is the founding and current CEO of the Structural Genomics Consortium (SGC), a professor at the University of Toronto and an adjunct professor at McGill University. The SGC has been sharing its science freely since 2003 and is widely acknowledged as a pioneer in open science.

Cheryl Arrowsmith is the Chief Scientist of the Toronto Node of the Structural Genomics Consortium (SGC), a multinational public-private partnership that supports the discovery of new medicines through protein-based open access research. She leads the SGC’s program to develop chemical probes to chromatin regulators for target validation. Cheryl is also Sr. Scientist at Princess Margaret Cancer Centre in Toronto. Her current research interests focus on structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer.

Adrian Carter is vice president and global head of Discovery Research Coordination at Boehringer Ingelheim where he is responsible for guiding research policy and strategy, as well as steering operational themes. His career at Boehringer Ingelheim spans over 35 years and his interests include the neurobiology of dopamine, noradrenaline and acetylcholine release as well as the role of glutamate receptors and voltage-dependent sodium channels in health and disease.

Deborah M. Rothman, PhD, has been a Director of Chemical Biology within Discovery Chemistry at Merck & Co since late 2016. In her role, she is responsible for developing and mentoring a team of synthetic chemists and chemical biologists as individual contributors and team leaders. She is further responsible for the Infectious Diseases and Cardiovascular and Metabolic Diseases programs within Chemical Biology, and has a passion for annotated small molecule sets as well as Diversity and Inclusion. Deborah has 15 years of industry experience, published as a lead and contributing author in multiple scientific journals, and holds two patents.

Peter Kirkpatrick is the chief editor of Nature Reviews Drug Discovery, where he has been an editor since the journal's launch in 2001, becoming the chief editor in 2004. Previously he gained a PhD for studies on the biosynthesis and mode of action of vancomycin group antibiotics at the Department of Chemistry, Cambridge University, UK. He is interested in all aspects of the drug discovery process, and in facilitating interactions between the disciplines involved, as well as between academia and industry.

Paul Workman is a multidisciplinary cancer research scientist, molecular pharmacologist and chemical biologist who has been responsible for the laboratory discovery and progression into the clinic of many innovative cancer drugs.

Suzana Petanceska is Director of the Office for Strategic Development and Partnerships in the Division of Neuroscience at the National Institute on Aging (NIA).  During her tenure at the NIA, she developed a number of research portfolios and innovative programs in basic and translational research for Alzheimer’s disease.